Psyence Biomedical (PBM) Non-Current Debt (2023)
Psyence Biomedical (PBM) posted Non-Current Debt of $1.6 million for Q3 2023.
Powered by 
Analysis
Psyence Biomedical (PBM) Non-Current Debt (2023) Analysis & Trends
Psyence Biomedical has reported Non-Current Debt for 1 years, with the latest figure at $1.6 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | - |
| 10 | Psyence Biomedical | 2.63 Mn | 2.63 Mn | - | - |